# IMU-838 and Oseltamivir in the Treatment of COVID-19

> **NCT04516915** · PHASE2 · COMPLETED · sponsor: **University Hospitals Coventry and Warwickshire NHS Trust** · enrollment: 38 (actual)

## Conditions studied

- Covid 19

## Interventions

- **DRUG:** IMU-838
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT04516915
- **Lead sponsor:** University Hospitals Coventry and Warwickshire NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-09-21
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516915, "IMU-838 and Oseltamivir in the Treatment of COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04516915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*